In-Silico RNA Therapeutic and Biomarker Discovery
Biomedical data might hold the key to finding the cure for currently incurable diseases. Our mission is to reduce the complexity of biomedical data into innovative therapeutic solutions.
We envision a future in which computerized predictive models will lower time and cost of drug development, impacting society with better and affordable treatments
How does SpliceCore work?
RNA-seq data analysis and interpretation in the cloud
Identify the best drug targets and biomarkers using RNA-seq
Splicing & Disease
Splicing Analysis is important to develop new drugs
a source of biological diversity
Splicing is the process of removal of non coding introns and assembly of coding exons into mature mRNAs. About 95% of human genes are alternatively spliced, leading to the expression of multiple mRNA form a same gene. While some splicing isoforms encode fully functional proteins, others lead to partially or non functional variants that can cause disease.
SPLICING AS A DRUG TARGET
A large number of diseases are caused by splicing defects
TYPICAL SPLICING ANALYSIS
This is how alternative splicing is usually analyzed
LIMITATIONS AND SOLUTIONS FOR SPLICING ANALYSIS
Envisagenics delivers the best isoform-level analysis of RNA-seq data
Envisagenics solution reaches the target. We use machine learning to predict disease-causing alternative splicing, drug targets and biomarkers.
PREDICTIVE-ANALYTICS FOR SPLICING ANALYSIS
Envisagencis' approach to prioritize drug targets and biomarkers
Who are we?
Maria Luisa Pineda Ph.D.
Dr. Maria Luisa Pineda is a biologist with over 10 years of research experience. For her undergraduate studies, Maria was awarded an endowment of $2 million dollars from the Goizueta Foundation and an NIH fellowship with the Minority Access to Research Careers (MARC U*STAR) program.
Maria received her Ph.D. from the prestigious Watson School of Biological Sciences at Cold Spring Harbor Laboratory as an Arnold and Mabel Beckman graduate student and a William Randolph Hearst foundation scholar. After graduating, she acquired investment experience in technology and life-sciences startup companies at Canrock Ventures and Golden Seeds, LLC.
Martin Akerman, Ph.D.
Dr. Martin Akerman was a postdoctoral fellow at Cold Spring Harbor Laboratory. He received his PhD in Bioinformatics from Technion - Israel, following his BSc and MSc in Biology also at the Technion. He started research as a cell biologist investigating infectious diseases.
He later transitioned into bioinformatics and developed new algorithms to analyze and interpret genomic data. Since the beginning of his PhD in 2005, his impact on the scientific community is reflected in over 600 citations in scientific journals. The software developed by Dr. Akerman is used by hundreds of scientists every month and has been experimentally validated in the field of cancer research.
Adrian Krainer, Ph.D.
Professor and Program Chair Cancer & Molecular Biology Cold Spring Harbor Laboratory.
Assistant Professor, Columbia University Core Member New York Genome Center.
Michael Schatz, Ph.D.
Associate research professor, Johns Hopkins University
Michael Q. Zhang, Ph.D.
Professor and Director Center for Systems Biology University of Texas at Dallas Professor, Tsinghua University.
News & press
Envisagenics at Grand Central Tech 2017 class
Investors & Partners
Request SpliceTrap download link
The use of SpliceTrap by academic users (academic institutions and non-profit organizations) requires the acceptance of Envisagenics standard end user license agreement and it is limited to internal research and development activities aimed at the production of scientific knowledge or teaching. It excludes any research activity by academic users sponsored by for-profit organizations and for any commercial use, whether it is to supply services to third parties or to sell information, data or any product of commercial value. Users desiring to use, copy, modify and/or incorporate Envisagenics' software into additional products or use it for commercial purposes require a partnership agreement.
Please contact Martin Akerman at [email protected]